CN115335367B - 用于炎性疾病和雄性避孕的RAR-α化合物 - Google Patents
用于炎性疾病和雄性避孕的RAR-α化合物 Download PDFInfo
- Publication number
- CN115335367B CN115335367B CN202080097179.0A CN202080097179A CN115335367B CN 115335367 B CN115335367 B CN 115335367B CN 202080097179 A CN202080097179 A CN 202080097179A CN 115335367 B CN115335367 B CN 115335367B
- Authority
- CN
- China
- Prior art keywords
- unsubstituted
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950473P | 2019-12-19 | 2019-12-19 | |
| US62/950,473 | 2019-12-19 | ||
| PCT/US2020/065719 WO2021127250A1 (en) | 2019-12-19 | 2020-12-17 | Rar-alpha compounds for inflammatory disease and male contraception |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115335367A CN115335367A (zh) | 2022-11-11 |
| CN115335367B true CN115335367B (zh) | 2024-08-13 |
Family
ID=74186909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080097179.0A Active CN115335367B (zh) | 2019-12-19 | 2020-12-17 | 用于炎性疾病和雄性避孕的RAR-α化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12492177B2 (https=) |
| EP (1) | EP4077300A1 (https=) |
| JP (1) | JP7657223B2 (https=) |
| CN (1) | CN115335367B (https=) |
| AU (1) | AU2020408043A1 (https=) |
| CA (1) | CA3165166A1 (https=) |
| WO (1) | WO2021127250A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12492177B2 (en) | 2019-12-19 | 2025-12-09 | Orphagen Pharmaceuticals, Inc. | RAR-α compounds for inflammatory disease and male contraception |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877207A (en) * | 1996-03-11 | 1999-03-02 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| WO2000019990A2 (en) * | 1998-10-08 | 2000-04-13 | Allergan Sales, Inc. | Rar antagonists as male anti-fertility agents |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US6521641B1 (en) * | 1998-10-08 | 2003-02-18 | Allergan, Inc. | Male anti-fertility agents |
| US20020193403A1 (en) | 2001-05-03 | 2002-12-19 | Allergan Sales, Inc. | Methods of treating hyperlipidemia |
| US7105566B2 (en) * | 2002-10-22 | 2006-09-12 | Allergan, Inc. | Methods of treatment during vascular procedures |
| DK3204357T3 (da) | 2014-10-10 | 2022-04-04 | High Force Res Limited | Fluorescerende, syntetiske retinoider |
| WO2017201200A1 (en) | 2016-05-19 | 2017-11-23 | Orphagen Pharmaceuticals, Inc. | Therapeutic compositions containing rar-alpha antagonists |
| DE102016123286B4 (de) | 2016-12-01 | 2019-03-07 | Deutsches Zentrum für Luft- und Raumfahrt e.V. | Verfahren und Vorrichtung zur Georeferenzierung von Luftbilddaten |
| EP3709990A4 (en) * | 2017-11-17 | 2021-12-01 | The Regents of the University of California | MANIPULATION OF THE RETIC ACID SIGNAL PATH |
| CN114041070B (zh) | 2018-11-19 | 2024-03-08 | 棱镜传感器公司 | 边缘式光子计数检测器 |
| US12492177B2 (en) | 2019-12-19 | 2025-12-09 | Orphagen Pharmaceuticals, Inc. | RAR-α compounds for inflammatory disease and male contraception |
-
2020
- 2020-12-17 US US17/786,399 patent/US12492177B2/en active Active
- 2020-12-17 EP EP20842449.9A patent/EP4077300A1/en active Pending
- 2020-12-17 CN CN202080097179.0A patent/CN115335367B/zh active Active
- 2020-12-17 AU AU2020408043A patent/AU2020408043A1/en active Pending
- 2020-12-17 JP JP2022537288A patent/JP7657223B2/ja active Active
- 2020-12-17 CA CA3165166A patent/CA3165166A1/en active Pending
- 2020-12-17 WO PCT/US2020/065719 patent/WO2021127250A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877207A (en) * | 1996-03-11 | 1999-03-02 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| WO2000019990A2 (en) * | 1998-10-08 | 2000-04-13 | Allergan Sales, Inc. | Rar antagonists as male anti-fertility agents |
Non-Patent Citations (1)
| Title |
|---|
| Identification of Highly Potent Retinoic Acid Receptorr-Selective Antagonists;Min Teng et al.;J. Med. Chem.;第40卷(第16期);第2445页Chart 3，第2447页Table 1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115335367A (zh) | 2022-11-11 |
| AU2020408043A1 (en) | 2022-07-28 |
| US20230357175A1 (en) | 2023-11-09 |
| WO2021127250A1 (en) | 2021-06-24 |
| JP2023509372A (ja) | 2023-03-08 |
| US12492177B2 (en) | 2025-12-09 |
| EP4077300A1 (en) | 2022-10-26 |
| JP7657223B2 (ja) | 2025-04-04 |
| CA3165166A1 (en) | 2021-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7664201B2 (ja) | アミロイド標的剤及びその使用方法 | |
| JP6122055B2 (ja) | 核内受容体結合剤 | |
| JP5815237B2 (ja) | 核内受容体結合剤 | |
| KR102868652B1 (ko) | Kv7 채널 활성화제 조성물 및 이의 사용 방법 | |
| CN102970870A (zh) | 核受体结合剂 | |
| CN108289960B (zh) | Ep4受体拮抗剂用于治疗nash相关肝癌的用途 | |
| JP2022095820A (ja) | ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法 | |
| JP2003507372A (ja) | 糖尿病を処置するための安息香酸誘導体 | |
| CN106536520A (zh) | 芳基受体调制剂及其制备和使用方法 | |
| KR20010032064A (ko) | ＩｇＥ의 조절제로서의 벤즈이미다졸 유도체 | |
| BR112015021371B1 (pt) | Uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares | |
| JP2022095809A (ja) | ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド１（ｐｄ－ｌ１）阻害剤とを含む医薬組み合わせ物及びその使用方法 | |
| CN105392498A (zh) | 抗恶性肿瘤剂组合物 | |
| JP2021518367A (ja) | Ｉｄｏおよびｔｄｏ調節のための化合物および方法、ならびにそれらのための兆候 | |
| KR20170131644A (ko) | 인단 아세트산 유도체를 사용한 간 질환의 치료 방법 | |
| CN115335367B (zh) | 用于炎性疾病和雄性避孕的RAR-α化合物 | |
| CA3217096A1 (en) | Contraceptive compounds and methods | |
| EP4117660B1 (en) | Methods of modulating t-cell activation and treating chronic heart failure using carboranes | |
| WO2025045124A1 (zh) | Soat1抑制剂及其应用 | |
| JP2024533229A (ja) | Ｂｃｎ０５７、ｂｃｎ０７７および類似体を用いた治療の方法 | |
| JP2026510946A (ja) | レチンアルデヒドデヒドロゲナーゼ１（ｒａｌｄｈ１）阻害剤および免疫賦活剤の組み合わせならびにそれらの使用方法 | |
| WO2019022501A1 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER COMPRISING A VASCULAR DISRUPTION AGENT AND AN IMMUNE CONTROL POINT INHIBITOR | |
| WO2025140721A1 (zh) | 腙类化合物、其药物组合物及其应用 | |
| HK40080138A (en) | Methods of modulating t-cell activation using carboranes and carborane analogs | |
| TW201144296A (en) | Tetrazolones as inhibitors of fatty acid synthase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |